TransIT®-BrCa Transfection Reagent – MIR 5500

Efficient delivery to many breast cancer cell types whilst maintaining low cellular toxicity

Reagent Agent®

Catalogue NumberDescriptionPack SizePrice
E7-0168TransIT®-BrCa Transfection Reagent – MIR 55001ml£504.00
TransIT®-BrCa Transfection Reagent is the first dedicated breast cancer cell line specific reagent available to researchers. While it delivers efficiently to many breast cancer cell types, it also maintains low cellular toxicity resulting in reduced experimental biases. Broad Spectrum DNA Delivery - Achieve high expression levels in multiple breast cancer cell types. Formulated for Low Cellular Toxicity - Maintain cell density and reduce experimental biases due to toxicity. Superior Transfection Efficiency - TransIT®-BrCa outperforms Lipofectamine™ 2000, in various breast cancer cell lines.


Figures Data
E7-0168 Fig 1


E7-0168 Protocol MIR5500
E7-0168 MSDS MIR5500
Catalogue NumberDescriptionPack SizePrice
K1-0210EZ-PCR Mycoplasma Test Kit20 Assays£224